Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 6 of 379 for:    addiction | Open Studies

Prognosis of Behavioral Addiction in Parkinson's Disease (PROBA-PD)

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified January 2016 by University Hospital, Strasbourg, France
Information provided by (Responsible Party):
University Hospital, Strasbourg, France Identifier:
First received: January 18, 2016
Last updated: January 28, 2016
Last verified: January 2016

Our hypothesis is that the conventional treatment of Behavioral Addiction in Parkinson's disease is often not effective, and that affects the motor aspects (worsening akinéto-rigid syndrome and / or worsening of dyskinesia due to higher levodopa doses to compensate for the drop in behavioral addictions) and non-motor (withdrawal syndrome dopamine agonist) anxiously including apathy.

Our goal is to describe the natural history of Behavioral Addiction under the effect of the evolution of the disease and adapt treatment according to the prior art, through a study of a larger population of patients than in the few published studies.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective

Resource links provided by NLM:

Further study details as provided by University Hospital, Strasbourg, France:

Primary Outcome Measures:
  • Survival time before disappearance of behavioral addiction defined by a score of less than 2 on the scale of behavioral assessment of Parkinson's disease [ Time Frame: 12 months after selection ]

Estimated Enrollment: 200
Study Start Date: February 2016
Estimated Study Completion Date: January 2021
Estimated Primary Completion Date: January 2021 (Final data collection date for primary outcome measure)
- Patients with behavioral addiction
- Patients with no behavioral addiction


Ages Eligible for Study:   30 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with Parkinson's disease who developed or not a behavioral addiction

Inclusion criteria:

  • Age greater than or equal to 30 years
  • Parkinson's disease according to the criteria of UKPDSBB
  • Time evolution of the top disease or equal to 5 years

Exclusion criteria:

  • Lack of Parkinson's disease and atypical parkinsonism
  • Patient not previously included in PD-BADGE
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02671240

Contact: Mathieu ANHEIM, MD, PhD 33 (0)3 88 12 85 32

Sponsors and Collaborators
University Hospital, Strasbourg, France
Study Director: Mathieu ANHEIM, MD, PhD University Hospital, Strasbourg, France
  More Information

Responsible Party: University Hospital, Strasbourg, France Identifier: NCT02671240     History of Changes
Other Study ID Numbers: 6246
Study First Received: January 18, 2016
Last Updated: January 28, 2016
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by University Hospital, Strasbourg, France:
Parkinson disease
behavioral addiction
akinéto-rigid syndrome
dopamine agonist

Additional relevant MeSH terms:
Parkinson Disease
Behavior, Addictive
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Compulsive Behavior
Impulsive Behavior processed this record on April 27, 2017